Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Zentalis Pharmaceuticals has received an average rating of "Moderate Buy" from six brokerages, with a consensus target price of $8.20.
• Institutional investors, including Deutsche Bank AG and Wealth Enhancement Advisory Services, have recently increased their stakes in Zentalis Pharmaceuticals, demonstrating growing confidence in the company.
• The company's stock is currently priced at $1.69, with a 12-month range between $1.01 and $5.44 and a reported EPS of ($0.37) that exceeded analysts' expectations.

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.20.

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Wall Street Zen raised Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 9th. Wedbush reissued a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Finally, HC Wainwright upgraded Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 7th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC raised its position in Zentalis Pharmaceuticals by 14.1% in the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock worth $173,000 after purchasing an additional 7,058 shares during the last quarter. Wells Fargo & Company MN raised its position in Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock worth $105,000 after purchasing an additional 7,305 shares during the last quarter. Cerity Partners LLC raised its position in Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after purchasing an additional 7,579 shares during the last quarter. Corton Capital Inc. bought a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $32,000. Finally, State of Wyoming boosted its stake in Zentalis Pharmaceuticals by 30.1% in the first quarter. State of Wyoming now owns 45,176 shares of the company's stock valued at $72,000 after acquiring an additional 10,460 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock traded down $0.04 during midday trading on Friday, reaching $1.68. 115,410 shares of the company's stock traded hands, compared to its average volume of 1,205,030. The company has a market cap of $120.83 million, a price-to-earnings ratio of -0.74 and a beta of 1.76. The company's 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.51. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.19. As a group, equities research analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.